The Antiepileptic Drug and Toxic Teratogen Valproic Acid Alters Microglia in an Environmental Mouse Model of Autism.
microglia
primary motor cortex
valproic acid
Journal
Toxics
ISSN: 2305-6304
Titre abrégé: Toxics
Pays: Switzerland
ID NLM: 101639637
Informations de publication
Date de publication:
09 Jul 2022
09 Jul 2022
Historique:
received:
17
06
2022
revised:
03
07
2022
accepted:
06
07
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Autism spectrum disorder (ASD), a neurodevelopmental condition affecting approximately 1 in 44 children in North America, is thought to be a connectivity disorder. Valproic acid (VPA) is a multi-target drug widely used to treat epilepsy. It is also a toxic teratogen as well as a histone deacetylase inhibitor, and fetal exposure to VPA increases the risk of ASD. While the VPA model has been well-characterized for behavioral and neuronal deficits including hyperconnectivity, microglia, the principal immune cells of CNS that regulate dendrite and synapse formation during early brain development, have not been well-characterized and may provide potential hints regarding the etiology of this disorder. Therefore, in this study, we determined the effect of prenatal exposure to VPA on microglial numbers during early postnatal brain development. We found that prenatal exposure to VPA causes a significant reduction in the number of microglia in the primary motor cortex (PMC) during early postnatal brain development, particularly at postnatal day 6 (P6) and postnatal day 10 (P10) in male mice. The early microglial reduction in the VPA model coincides with active cortical synaptogenesis and is significant because it may potentially play a role in mediating impaired connectivity in ASD.
Identifiants
pubmed: 35878284
pii: toxics10070379
doi: 10.3390/toxics10070379
pmc: PMC9319720
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103408
Pays : United States
Références
Prog Neurobiol. 2017 Feb - Mar;149-150:1-20
pubmed: 28143732
Brain Behav Immun. 2011 Jan;25(1):40-5
pubmed: 20705131
Int J Dev Neurosci. 2021 Feb;81(1):37-50
pubmed: 33107086
PLoS One. 2011;6(5):e20470
pubmed: 21647375
J Autism Dev Disord. 2006 Aug;36(6):779-93
pubmed: 16609825
J Child Neurol. 1994 Jan;9(1):77-80
pubmed: 8151090
Ann Neurol. 2005 Jan;57(1):67-81
pubmed: 15546155
J Neuroinflammation. 2011 May 19;8:52
pubmed: 21595886
Neurotoxicol Teratol. 2013 Mar-Apr;36:67-81
pubmed: 22918031
Cell Rep. 2013 Nov 14;5(3):738-47
pubmed: 24210821
J Neuroimmunol. 2009 Feb 15;207(1-2):111-6
pubmed: 19157572
J Neuroimmunol. 2008 Nov 15;204(1-2):149-53
pubmed: 18762342
Pediatr Neurol. 2007 Jun;36(6):361-5
pubmed: 17560496
Science. 2011 Sep 9;333(6048):1456-8
pubmed: 21778362
Int J Mol Sci. 2020 May 18;21(10):
pubmed: 32443651
Front Neural Circuits. 2008 Oct 29;2:4
pubmed: 18989389
Brain. 2008 Apr;131(Pt 4):1000-12
pubmed: 18234695
Neuroscience. 2006 Jul 21;140(4):1149-56
pubmed: 16600518
Nat Neurosci. 2004 Apr;7(4):327-32
pubmed: 15048120
Psychoneuroendocrinology. 2016 Oct;72:11-21
pubmed: 27337090
Brain Dev. 2007 Oct;29(9):565-70
pubmed: 17467940
Cereb Cortex. 2008 Apr;18(4):763-70
pubmed: 17638926
Cold Spring Harb Perspect Biol. 2012 Mar 01;4(3):
pubmed: 22258914
Cell Rep. 2017 Jan 31;18(5):1100-1108
pubmed: 28147267
J Neuropathol Exp Neurol. 2007 May;66(5):372-82
pubmed: 17483694
Nat Neurosci. 2014 Mar;17(3):400-6
pubmed: 24487234
Dev Psychobiol. 2008 Nov;50(7):633-9
pubmed: 18985861
Curr Opin Neurol. 2015 Apr;28(2):91-102
pubmed: 25695134
Neuron. 2012 May 24;74(4):691-705
pubmed: 22632727